Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-re
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
10:01am, Friday, 11'th Dec 2020
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT® EPA, Primary Results of the VASCEP
These are the stocks seeing the most insider buying this week
07:11am, Friday, 04'th Dec 2020
Brian Sullivan on the top companies this week whose executives are purchasing their own stock, on Worldwide Exchange.
Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)
12:57pm, Wednesday, 02'nd Dec 2020
Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)
Amarin Files Patent Infringement Lawsuit Against Hikma
07:55pm, Monday, 30'th Nov 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a li
Amarin: There's Still Some Fight Left In This Stock
03:58pm, Monday, 23'rd Nov 2020
Amarin lost its generic appeal and the stock has faltered badly. People are possibly ignoring the vast European market and also what's left of the US market may be protected by manufacturing hurdles.
Buy Amarin And Bet On Its Recovery In 2021
07:57am, Monday, 23'rd Nov 2020
Amarin's legal loss at the U.S. appeals court sent the stock lower. Positive clinical data from China partner a catalyst.
Amarin vs. the Generics: Who Will Win?
06:28am, Sunday, 22'nd Nov 2020
After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.
AMRN Stock News: Why Amarin Shares Are Climbing Today
11:41am, Friday, 20'th Nov 2020
AMRN stock is climbing higher Thursday thanks to good news from a clinical trial in China. Here's what you should know about Amarin now.
Amarin Shares Topline Data from Partner's Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China
06:30pm, Thursday, 19'th Nov 2020
Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol ( LDL-C ) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose
Amarin Corporation PLC (AMRN) Presents at Jefferies Virtual London Healthcare Broker Conference Call - (Transcript)
01:51pm, Thursday, 19'th Nov 2020
Amarin Corporation PLC (AMRN) Presents at Jefferies Virtual London Healthcare Broker Conference Call - (Transcript)
Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effective ness in reducing major adverse cardiovascular events (MACE) in studied high-
Amarin Corporation plc (AMRN) Presents at Stifel Virtual Healthcare Conference (Transcript)
11:19am, Monday, 16'th Nov 2020
Amarin Corporation plc (AMRN) Presents at Stifel Virtual Healthcare Conference (Transcript)
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual Scientific Sessions 2020
10:00am, Friday, 13'th Nov 2020
VASCEPA®, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events ( MACE ) in post hoc exploratory analyses of patients with a history of CA
